09939.HK
Kintor Pharmaceutical Limited
HKSE · Healthcare · Biotechnology · CN
HKD 1.35
−6.25%Year over year
Reported trailing growth
- Revenue
- +554.4%
- EBITDA
- -11.1%
- EBIT
- -5.4%
- EPS
- -2.5%
- Free cash flow
- +42.0%
- Operating cash flow
- +11.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +553.6%
- EBITDA
- -8.5%
- EBIT
- -38.2%
- Net income
- -28.9%
- EPS
- -22.2%
- Free cash flow
- +17.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026